John H Marks, MD, FACS, FASCRS (Colorectal Surgery)
Chief, Colon & Rectal Surgery
Director, Minimally Invasive Colorectal Surgery and Advanced Rectal Cancer Management Fellowship
Professor, Lankenau Institute of Medical Research
Division of Colorectal Surgery, Lankenau Medical Center, Wynnewood, PA, USA
John H Marks, MD., FACS, FASCRS, is an internationally renowned colorectal surgeon with recognized areas of expertise in rectal cancer management and laparoscopic and robotic surgery. Dr. Marks is currently the Director of the Colorectal Surgery Center and Chief of the Section of Colorectal Surgery for The Main Line Health System at the Lankenau Medical Center in Wynnewood, Pennsylvania, USA. Dr. Marks is the Director of a Fellowship in Minimally Invasive Colorectal Surgery and Advanced Rectal Cancer Management as well as a colorectal surgical research team. As one of the world’s most experienced colorectal surgeons, he has performed nearly 3000 minimally invasive colorectal cancer surgeries, including more than 1400 rectal cancer procedures. Dr. Marks’ research and educational programs focus largely on minimally invasive laparoscopic and robotic colorectal surgery featuring radical sphincter preservation resection for rectal cancer after neoadjuvant therapy, one of the largest series of its kind in the world. He champions Full Thickness Local Excision (FTLE) by the Transanal Endoscopic Microsurgical (TEM) method following neoadjuvant therapy for rectal cancer and has performed over 400 TEMs to date. Dr. Marks remains on the leading edge of advancements in colorectal surgery, having performed over 300 single-incision laparoscopic surgeries (SILS). He is currently collaborating on applications for robotic single port surgery to expand endoluminal and SILS for a variety of pathologies and Lankenau will be one of the first three centers in the world to have the new SP robot. With Dr. Marks leading Lankenau Medical Center, one of four academic colorectal robotic Epicenters in the country, he has performed over 275 surgeries with the DaVinci Si and Xi robots. He and his colleagues frequently publish findings from a robust and rigorously maintained patient database, including a 2017 report of low local recurrence and excellent 5-year survival in 373 patients undergoing transanal total mesorectal excision (taTME) for rectal cancer. Dr. Marks’ experience in advanced rectal cancer surgery led to Lankenau being selected in 2018 to participate in a 5-year multicenter phase II study of taTME. Dr. Marks recently published a book “Surgical Techniques in Rectal Cancer – Transanal, Laparoscopic and Robotic Approach”, the first significant text dedicated to the surgical treatment of rectal cancer in over a decade. Dr. Marks is happy to showcase experts and their contributions to rectal cancer surgery to the world.